In metastatic non-small cell lung cancer (NSCLC) harboring driver mutations (e.g., EGFR, ALK, or ROS1), targeted therapies are usually preferred over other approaches since they have been found effective and to have tolerable toxicity. Here, EGFR is linked to non-small cell lung carcinoma.